Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of oncology drug candidates based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has begun in Poland recruiting patients in the Company’s second clinical trial to
Flex Pharma, Inc. and Salarius Pharmaceuticals, LLC, a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that the companies have entered into a definitive merger agreement under which privately-held Salarius will merge with a wholly-owned subsidiary of Flex Pharma.
Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that in preliminary animal studies, a second of its lead
Forbius, a clinical-stage company developing biologics for the treatment of fibrosis and cancer, announced today that Ilia Tikhomirov, CEO of Forbius, will be presenting at the 37th Annual J.P. Morgan Healthcare Conference. Mr. Tikhomirov’s presentation will take place Wednesday, January 9th at 11:30 a.m. PST in Elizabethan D at the Westin St.
Clinical study demonstrates proof-of-concept for active personalized immunotherapy approach in a pioneering multi-center, multi-national study to treat brain cancer. This study is a blueprint for Immatics’ highly personalized ACTolog® adoptive cell therapy trial currently treating patients at MD Anderson Cancer Center.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline results from Phase 1 clinical studies of LX2761, an oral sodium-glucose cotransporter type 1 (SGLT1) inhibitor in development for the treatment of diabetes.
Forbius, a clinical-stage company developing biologics for the treatment of cancer and fibrosis, announced that its Chief Scientific Officer, Maureen O’Connor, will be giving an oral presentation reporting on AVID200’s broad activity in fibrotic diseases at the Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD.
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported safety and promising activity of BPX-601 in Part 1 of a Phase 1/2 dose-escalation study in patients with advanced, metastatic pancreatic cancer expressing PSCA (prostate stem cell antigen).